FDA |
Food and Drug Administration |
MMR |
mismatch repair |
IHC |
immunohistochemistry |
MLH1 |
mutL homologue 1 |
MSH2 |
mutS homologue 2 |
MSH6 |
mutS homologue 6 |
PMS2 |
postmeiotic segregation increased 2 |
MSI |
Microsatellite instability |
hMMR |
MMR-heterogeneous |
dMMR |
MMR-deficient |
pMMR |
MMR-proficient |
PTEN |
Phosphatase and tensin homolog |
PI3K |
phosphatidylinositol-3-kinase |
Akt |
protein kinase B |
BCIRG |
Breast Cancer International Research Group |
ER |
estrogen receptor |
SCNA |
somatic copy number alteration |
HR |
hazard ratio |
PPV |
positive predictive value |
PR |
progesterone receptor |
LDT |
locally developed tests |
TNBCs |
triple-negative breast cancers |
TMAs |
tissue microarrays |
PD-L1 |
programmed death-ligand 1 |
IRB |
Institutional Review Board |
SD |
standard deviation |
WHO |
World Health Organization |
AJCC |
American Joint Committee on Cancer |
FFPE |
formalin-fixed, paraffin-embedded |
CAP |
College of American Pathologists |
OR |
odds ratio |
CI |
confidence interval |